Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with A / Amisulpride 		 
Amisulpride
  

Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.
BrandsDeniban
Solian
CategoriesDopamine Antagonists
Antipsychotic Agents
SynonymsAminosultopride

indication

Investigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression.

mechanism of action

Amisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment.

toxicity

Overdoses of amisulpride have been linked with torsades de pointes.

absorption

Bioavailability is 48% following oral administration.

half life

Approximately 12 hours

Terms of Use